[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353403-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353403-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hpv-testing-versus-cytology-for-cervical-cancer-screening-among-women-50-years-and-older-evidence-from-the-hpv-focal-randomized-controlled-trial","HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older - Evidence From the HPV FOCAL Randomized Controlled Trial","","Evidence on the comparative effectiveness of HPV testing versus cytology for women aged ≥50 years near screening cessation remains limited. Analysis used baseline data from 6471 women in the HPV FOCAL randomized clinical trial. Participants were assigned to cytology (n=3248) or HPV testing (n=3223) and compared CIN2+ incidence rates, risk ratios, and missed exit lesions. At 48 months, CIN2+ detection was lower with HPV baseline-negative results than with cytology, with a hazard ratio of 0.44 after adjustment, supporting HPV primary screening in this age group.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hpv-testing-versus-cytology-for-cervical-cancer-screening-among-women-50-years-and-older-evidence-from-the-hpv-focal-randomized-controlled-trial/353403/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hpv-testing-versus-cytology-for-cervical-cancer-screening-among-women-50-years-and-older-evidence-from-the-hpv-focal-randomized-controlled-trial/353403.png","ImageObject",300,407,{"name":42,"@type":43},"hdkawk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were women assigned to screening methods in the HPV FOCAL trial?","Question",{"text":63,"@type":64},"Women aged 50 and older were randomly allocated to receive cytology or HPV testing at baseline, with co-testing at the 48-month exit.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the study find about CIN2+ detection at the 48-month exit?",{"text":68,"@type":64},"CIN2+ detection was lower among HPV baseline-negative women than among those in the cytology group, with risk ratio 0.51 (95% CI, 0.11–0.91).",{"name":70,"@type":61,"acceptedAnswer":71},"How did HPV testing compare with cytology after a negative HPV test?",{"text":72,"@type":64},"After adjustment, HPV testing showed a continued lower subsequent risk for CIN2+ compared with cytology, supporting HPV primary screening use in this age cohort.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353403,1790164502,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","International Journal of Cancer  \nRESEARCH ARTICLE  OPEN ACCESS   \nInnovative Tools and Methods  \nHPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial  \nMd Saiful Alam1  | Laurie W. Smith2 | Lovedeep Gondara1 | Darrel Cook3  | Ruth Elwood Martin1 | Stuart Peacock4,5  | Lily Proctor1,6 | Gavin Stuart1 | David Patrick1 | Eduardo L. Franco7  | Mel Krajden1,3 | Anna Gottschlich8  | Gina S. Ogilvie1,2   \n1University of British Columbia, Vancouver, British Columbia, Canada | 2Women's Health Research Institute, BC Women's Hospital and Health Service, Vancouver, British Columbia, Canada | 3British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada | 4Population Health Sciences, BC Cancer, Vancouver, British Columbia, Canada | 5Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada | 6Cervical Screening Program, British Columbia Cancer, Vancouver, British Columbia, Canada | 7Division of Cancer Epidemiology, McGill  \nUniversity, Montreal, Quebec, Canada | 8Department of Oncology, Karmanos Cancer Institute, Wayne State School of Medicine, Detroit, Michigan, USA Correspondence: Gina S. Ogilvie ([gina.ogilvie@bccdc.ca](gina.ogilvie@bccdc.ca))  \nReceived: 21 February 2026 | Revised: 31 May 2026 | Accepted: 10 June 2026  \nKeywords: cervical cancer screening | cervical intraepithelial neoplasia (CIN) | human papillomavirus (HPV) | randomized controlled trial | women aged 50 and older  \nABSTRACT  \nEvidence on the comparative effectiveness of HPV testing versus cytology specifically in women aged ≥50years who are approaching screening cessation remains limited. This analysis included 6471 women aged ≥50 at baseline screening in the HPV FOCAL randomized clinical trial. Women were randomly allocated to receive cytology (Control Group, n = 3248, 50.19%) or HPV testing (Intervention Group, n = 3223, 49.81%) at baseline, with co-testing at 48-month exit. We calculated incidence rates and risk ratios for CIN2+ detection over follow-up and compared missed lesions at exit by screening method. At the 48-month exit, CIN2+ detection was lower among HPV baseline-negative women than among those in the cytology group (1.61/1000 [95% CI, 0.52–3.76] vs. 3.15/1000 [95% CI, 1.51–5.78]; risk ratio, 0.51 [95% CI, 0.11–0.91]), reflecting higher baseline detection with HPV testing and fewer prevalent lesions at exit. Even with cytology re-screening at 2years, 50% ofCIN2+ cases were missed compared to 30% with HPV testing. After adjusting for age, education, smoking status, and lifetime sexual partners, the hazard ratio for CIN2+ comparing HPV to cytology was 0.44 (95% CI, 0.22–0.88). Among women aged ≥50years, HPV primary screening was more effective than cytology at detecting CIN2+ lesions and was associated with a continued lower subsequent risk following a negative HPV test, supporting its use in cervical cancer screening programs in this age cohort.  \n\n| Abbreviations: ACS, American Cancer Society; ASCUS, Atypical Squamous Cells of Undetermined Significance; BC, British Columbia; CCS, cervical cancer screening; CI, confidence interval; CIN, cervical intraepithelial neoplasia; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; CPAC, Canadian Partnership Against Cancer; HIV, human immunodeficiency virus; HPV, human papillomavirus; HPV FOCAL, Human Papillomavirus FOr CervicAL Cancer (randomized clinical trial); HR, hazard ratio; LBC, liquid-based cytology; LSIL, Low-grade Squamous Intraepithelial Lesion; RCT, randomized clinical trial; RR, risk ratio; USPSTF, United States Preventive Services Task Force; WHO, World Health Organization.\u003Cbr>Previous Presentation: Portions of this work were previously presented at the following conferences: (1) EUROGIN International Multidisciplinary HPV Congress 2024, Stockholm, Sweden, March 16, 2024 (Oral). (2) Ninth An","cbCaihsxceyFQ2Lc","https://ap.wps.com/l/cbCaihsxceyFQ2Lc","pdf",1086136,"English","# Abstract\n# Introduction\n# Evidence From the HPV FOCAL Randomized Controlled Trial\n## Comparative effectiveness outcomes (CIN2+ detection, missed lesions, risk after negative HPV)","[{\"question\":\"How were women assigned to screening methods in the HPV FOCAL trial?\",\"answer\":\"Women aged 50 and older were randomly allocated to receive cytology or HPV testing at baseline, with co-testing at the 48-month exit.\"},{\"question\":\"What did the study find about CIN2+ detection at the 48-month exit?\",\"answer\":\"CIN2+ detection was lower among HPV baseline-negative women than among those in the cytology group, with risk ratio 0.51 (95% CI, 0.11–0.91).\"},{\"question\":\"How did HPV testing compare with cytology after a negative HPV test?\",\"answer\":\"After adjustment, HPV testing showed a continued lower subsequent risk for CIN2+ compared with cytology, supporting HPV primary screening use in this age cohort.\"}]","HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older - Evidence From the HPV FOCAL Randomized Controlled Trial | PDF",1790105149,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c842b0db72002d94d7f2fd02ba6ef768.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8be1e6f146616bdea3bb98d52801afe9.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3a80e52dd38516afa047ddd98758f7f.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00cbc1ab06ee58e8a210855c9d708f77.webp",980,1287]